Jiangsu Hengrui Medicine Co., Ltd.

600276

CNE0000014W7

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

19,611

Sector

Pharmaceuticals

Calendar

2024-10-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.55CNY

Average target price

58.20CNY

Spread / Average Target

+30.63%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2024-09-09			5-day change	1st Jan Change
44.55 ^CNY	+0.34%		+1.48%	-1.50%

Sep. 05	Hengrui Medicine Gets China Nod for Anti-Hair Loss Drug	MT
Aug. 30	Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs	MT

Hengrui Medicine Gets China Nod for Anti-Hair Loss Drug	Sep. 05	MT
Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs	Aug. 29	MT
Jiangsu Hengrui Medicine Fiscal 2024 Profit Up 49%, Operating Income Rises 22%; Shares Up 3%	Aug. 21	MT
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 21	CI
Jiangsu Hengrui Medicine Gets Approval for Clinical Trial of Autoimmune Injection	Aug. 16	MT
Hengrui Pharmaceuticals Gets Nod to Trial Tablets to Treat Uterine Fibroids with Menorrhagia	Aug. 14	MT
Hengrui Pharmaceuticals Gets Nod to Add Indication for Paclitaxel for Injection; Shares Up 3%	Aug. 12	MT
Hengrui Pharmaceuticals Gets Nod to Trial Tumor Drug	Aug. 09	MT
Shanghai Medicilon Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd Deepen Strategic Collaboration to Support Innovation in Adcs, Small Nucleic Acids, and Cgt Drugs	Jul. 31	CI
Hengrui Pharmaceuticals' Unit Gets Nod to Trial Tumor Drug	Jul. 29	MT
Hengrui Medicine Gets Nod to Trials Breast Cancer Drugs	Jul. 29	MT
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral	Jul. 23	MT
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Liver Disease Treatment	Jul. 22	MT
Jiangsu Hengrui Medicine Vows to Improve Production Following FDA Warning	Jul. 18	MT
Hengrui Medicine Gets Inspection Clearance from Jiangsu Province's Drug Regulator	Jul. 08	MT
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug	Jul. 05	MT
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine	Jul. 03	MT
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China	Jul. 03	CI
Jiangsu Hengrui Medicine Gets US FDA Approval for Anesthetic; Shares Rise 4%	Jul. 03	MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic	Jul. 02	DJ
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.	Jul. 01	CI
Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs	Jun. 17	MT
Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug	Jun. 05	MT
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug	May. 29	MT
China Grants Clinical Trial Approval for Anti-Cancer Injections	May. 27	MT

Jiangsu Hengrui Medicine Co., Ltd.

Equities